company background image
LOGC logo

LogicBio Therapeutics NasdaqGM:LOGC Stock Report

Last Price

US$2.07

Market Cap

US$68.2m

7D

0.5%

1Y

-40.3%

Updated

16 Nov, 2022

Data

Company Financials +

LogicBio Therapeutics, Inc.

NasdaqGM:LOGC Stock Report

Market Cap: US$68.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

LOGC Stock Overview

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms.

LOGC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

LogicBio Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for LogicBio Therapeutics
Historical stock prices
Current Share PriceUS$2.07
52 Week HighUS$3.63
52 Week LowUS$0.26
Beta4.62
1 Month Change0.98%
3 Month Change417.63%
1 Year Change-40.35%
3 Year Change-76.79%
5 Year Changen/a
Change since IPO-82.00%

Recent News & Updates

LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion

Oct 03

Recent updates

LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion

Oct 03

Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

Aug 20
Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 18
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

LogicBio GAAP EPS of -$0.15, revenue of $3.2M

Aug 15

Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Jan 11
Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Aug 18
Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

LogicBio EPS misses by $0.06, beats on revenue

May 10

LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo

Apr 27

Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Apr 12
Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

Mar 08
Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

Jan 15
The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

LogicBio extends collaboration with Children's Medical Research Institute

Jan 07

LogicBio Therapeutics names new CFO

Dec 22

Looking In On LogicBio

Nov 17

LogicBio reports Q3 results

Nov 09

Shareholder Returns

LOGCUS BiotechsUS Market
7D0.5%0.2%1.3%
1Y-40.3%10.2%29.8%

Return vs Industry: LOGC underperformed the US Biotechs industry which returned -15.1% over the past year.

Return vs Market: LOGC underperformed the US Market which returned -21.9% over the past year.

Price Volatility

Is LOGC's price volatile compared to industry and market?
LOGC volatility
LOGC Average Weekly Movement179.9%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: LOGC's share price has been volatile over the past 3 months.

Volatility Over Time: LOGC's weekly volatility has increased from 92% to 180% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201462Fred Chereauhttps://www.logicbio.com

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company’s GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.

LogicBio Therapeutics, Inc. Fundamentals Summary

How do LogicBio Therapeutics's earnings and revenue compare to its market cap?
LOGC fundamental statistics
Market capUS$68.23m
Earnings (TTM)-US$26.54m
Revenue (TTM)US$10.76m

6.3x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LOGC income statement (TTM)
RevenueUS$10.76m
Cost of RevenueUS$30.68m
Gross Profit-US$19.92m
Other ExpensesUS$6.62m
Earnings-US$26.54m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.81
Gross Margin-185.15%
Net Profit Margin-246.71%
Debt/Equity Ratio37.7%

How did LOGC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.